InflaRx N.V. Common Stock
IFRXStock
$1.91+148.16%52W
Market Cap$323.76M
P/E—
Div yield—
Beta2.51
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)58.87%
Price vs S&P 500 (4W)25.65%
VGM Score35.23
Market Capitalization$323.76M
Earnings Surprise History
Q1 26-0.09est. -0.12
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.07
4.07
4.07
4.14
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
IFRXInflaRx N.V. Common Stock | F | F | A | $1.91 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
InflaRx NV is a clinical-stage biopharmaceutical company developing targeted therapies for autoimmune and inflammatory diseases. The company's lead candidate, vilobelimab, is a first-in-class monoclonal antibody designed to inhibit C5a, a key inflammatory mediator implicated in multiple disease pathways. Clinical data has demonstrated disease-modifying activity and a favorable safety profile. The company is advancing this platform with plans to address multiple therapeutic indications.